CoChat
Sign Up
Cited by 879

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Cancer nanomedicine: a review of recent success in drug delivery

Tran, Stephanie, DeGiovanni, Peter‐Joseph, Piel, Brandon, Rai, Prakash·2017·Clinical and Translational Medicine
DOI 10.1186/s40169-017-0175-0PMC PMC5725398
Open this paper in CoChat — free account

Abstract

Cancer continues to be one of the most difficult global healthcare problems. Although there is a large library of drugs that can be used in cancer treatment, the problem is selectively killing all the cancer cells while reducing collateral toxicity to healthy cells. There are several biological barriers to effective drug delivery in cancer such as renal, hepatic, or immune clearance. Nanoparticles loaded with drugs can be designed to overcome these biological barriers to improve efficacy while reducing morbidity. Nanomedicine has ushered in a new era for drug delivery by improving the therapeutic indices of the active pharmaceutical ingredients engineered within nanoparticles. First generation nanomedicines have received widespread clinical approval over the past two decades, from Doxil ® (liposomal doxorubicin) in 1995 to Onivyde ® (liposomal irinotecan) in 2015. This review highlights the biological barriers to effective drug delivery in cancer, emphasizing the need for nanoparticles for improving therapeutic outcomes. A summary of different nanoparticles used for drug delivery applications in cancer are presented. The review summarizes recent successes in cancer nanomedicine in the clinic. The clinical trials of Onivyde leading to its approval in 2015 by the Food and Drug Adminstration are highlighted as a case study in the recent clinical success of nanomedicine against cancer. Next generation nanomedicines need to be better targeted to specifically destroy cancerous tissue, but face several obstacles in their clinical development, including identification of appropriate biomarkers to target, scale‐up of synthesis, and reproducible characterization. These hurdles need to be overcome through multidisciplinary collaborations across academia, pharmaceutical industry, and regulatory agencies in order to achieve the goal of eradicating cancer. This review discusses the current use of clinically approved nanomedicines, the investigation of nanomedicines in clinical trials, and the challenges that may hinder development of the nanomedicines for cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40169-017-0175-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 10 references

Research works printed but not linked: 80

  1. 10.3322/caac.21395 · DOI
  2. 10.1016/j.jconrel.2014.12.030 · DOI
  3. 10.1158/1535-7163.MCT-06-0141 · DOI
  4. 10.1146/annurev-bioeng-071811-150124 · DOI
  5. 10.1016/j.nano.2015.08.006 · DOI
  6. 10.1517/17425247.2014.950564 · DOI · Paper page
  7. 10.1016/j.bpj.2010.06.016 · DOI
  8. Locatelli E, 2012, Biodegradable PLGA‐b‐PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system, J Nanopart Res, 14, 1, 10.1007/s11051-012-1316-4 · DOI
  9. 10.1016/j.jconrel.2012.01.043 · DOI
  10. 10.1016/j.tibtech.2016.07.006 · DOI · Paper page
  11. 10.1158/1078-0432.CCR-07-1441 · DOI
  12. 10.1021/mp100253e · DOI
  13. 10.1039/C6TB00847J · DOI
  14. 10.1002/cbf.1149 · DOI
  15. Chen K‐J, 2012, A thermoresponsive bubble‐generating liposomal system for triggering localized extracellular drug delivery, ACS Nano, 7, 438, 10.1021/nn304474j · DOI
  16. 10.1016/j.jconrel.2014.05.002 · DOI
  17. 10.1093/jnci/djm043 · DOI
  18. 10.1038/srep02953 · DOI
  19. 10.1016/j.jconrel.2004.11.023 · DOI
  20. Wang L, 2017, Multifunctional telodendrimer nanocarriers restore synergy of bortezomib and doxorubicin in ovarian cancer treatment, Can Res, 77, 3293, 10.1158/0008-5472.CAN-16-3119 · DOI
  21. 10.1021/nn3044066 · DOI
  22. 10.1021/acs.molpharmaceut.6b00388 · DOI
  23. Ahmed N, 2012, Theranostic applications of nanoparticles in cancer, Drug Discov Today, 17, 928, 10.1016/j.drudis.2012.03.010 · DOI
  24. 10.1016/j.addr.2010.09.002 · DOI
  25. 10.1002/smll.201303540 · DOI
  26. 10.1504/IJNM.2009.028116 · DOI
  27. 10.1126/science.1229568 · DOI
  28. 10.1088/0957-4484/22/11/115101 · DOI
  29. 10.2217/nnm.13.191 · DOI
  30. 10.1152/ajprenal.00290.2001 · DOI
  31. Liu J, 2013, Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology, Mater Today, 16, 477, 10.1016/j.mattod.2013.11.003 · DOI
  32. 10.1073/pnas.0913667107 · DOI
  33. 10.1016/B978-0-12-391860-4.00006-9 · DOI
  34. 10.1602/neurorx.2.1.3 · DOI · Paper page
  35. 10.1016/j.ejpb.2008.08.021 · DOI · Paper page
  36. 10.1124/jpet.105.097139 · DOI · Paper page
  37. 10.1016/j.jconrel.2008.10.016 · DOI
  38. 10.1007/s00018-007-6390-x · DOI
  39. 10.1186/s12951-015-0075-7 · DOI
  40. 10.1080/10611860400015936 · DOI
  41. ShankerSharma H, 2012, Neurotoxicity of engineered nanoparticles from metals, CNS Neurol Disord Drug Targets, 11, 65, 10.2174/187152712799960817 · DOI
  42. 10.1016/j.toxlet.2012.08.009 · DOI
  43. 10.1021/nn400548g · DOI
  44. Alley SC, 2010, Antibody–drug conjugates: targeted drug delivery for cancer, Curr Opin Chem Biol, 14, 529, 10.1016/j.cbpa.2010.06.170 · DOI
  45. 10.1016/j.cbpa.2009.03.023 · DOI
  46. 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10 · DOI
  47. 10.1126/science.364652 · DOI
  48. 10.1016/j.addr.2008.03.007 · DOI
  49. 10.1021/mp400190z · DOI
  50. 10.1016/j.polymer.2008.01.027 · DOI
  51. 10.1021/ja053962k · DOI
  52. 10.2147/IJN.S112660 · DOI
  53. 10.1126/science.275.5297.187 · DOI
  54. Almajhdi F, 2014, In‐vitro anticancer and antimicrobial activities of PLGA/silver nanofiber composites prepared by electrospinning, J Mater Sci, 25, 1045
  55. Elbaz NM, 2016, Core‐shell silver/polymeric nanoparticles‐based combinatorial therapy against breast cancer in‐vitro, Sci Rep, 6, 30729, 10.1038/srep30729 · DOI
  56. 10.1016/S0021-9258(17)38654-4 · DOI · Paper page
  57. Hsiang Y‐H, 1989, Arrest of replication forks by drugstabilized topoisomerase I‐DNA cleavable complexes as a mechanism of cell killing by camptothecin, Can Res, 49, 5077
  58. Zamboni WC, 2005, Relationship between plasma exposure of 9‐nitrocamptothecin and its 9‐aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts, Clin Cancer Res, 11, 4867, 10.1158/1078-0432.CCR-05-0144 · DOI
  59. 10.2217/fon.15.333 · DOI
  60. 10.1158/0008-5472.CAN-05-4007 · DOI
  61. Chiang N‐J, 2016, A phase I dose‐escalation study of PEP02 (irinotecan liposome injection) in combination with 5‐fluorouracil and leucovorin in advanced solid tumors, BMC Cancer, 16, 907, 10.1186/s12885-016-2933-6 · DOI
  62. 10.1093/annonc/mdt002 · DOI
  63. Pan X, 2017, Construction of anti‐EGFR immunoliposomes via folate‐folate binding protein affinity, Int J Pharm, 336, 276, 10.1016/j.ijpharm.2006.12.007 · DOI
  64. 10.1038/bjc.2013.408 · DOI
  65. Stubbs M, 1994, Metabolic consequences of a reversed pH gradient in rat tumors, Cancer Res, 54, 4011
  66. 10.1038/nature07943 · DOI
  67. TinkleS McNeilSE MϋhlebachS BawaR BorchardG BarenholzYC TamarkinL DesaiN(2014)Nanomedicines: addressing the scientific and regulatory gap. Ann NY Acad Sci 1313:35–56 · DOI
  68. Ma MK, 2000, Pharmacokinetics of irinotecan and its metabolites SN‐38 and APC in children with recurrent solid tumors after protracted low‐dose irinotecan, Clin Cancer Res, 6, 813
  69. Cainelli F, 2009, Safety and efficacy of pegylated liposomal doxorubicin in HIV‐associated Kaposi’s sarcoma, Biologics, 3, 385
  70. Chen L, 2010, Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5‐FU/LV in advanced solid tumors, J Clin Oncol, 28, e13024, 10.1200/jco.2010.28.15_suppl.e13024 · DOI
  71. 10.1158/1078-0432.CCR-03-0655 · DOI · Paper page
  72. Ledet G, 2012, Nanomedicine: emerging therapeutics for the 21st century, US Pharm, 37, 7
  73. 10.1007/s00280-012-2042-4 · DOI
  74. Young C, 2011, CRLX101 (formerly IT‐101)—a novel nanopharmaceutical of camptothecin in clinical development, Current Bioactive Compd, 7, 8, 10.2174/157340711795163866 · DOI
  75. 10.1016/j.ijpharm.2006.12.007 · DOI
  76. Li C, 2014, Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose‐dependent activity saturation effect, Int J Pharm, 460, 165, 10.1016/j.ijpharm.2013.10.023 · DOI
  77. 10.1016/j.ejpb.2008.05.019 · DOI
  78. 10.1002/cncr.28974 · DOI · Paper page
  79. 10.1038/mt.2013.32 · DOI
  80. Young C, 2011, CRLX101 (formerly IT‐101) a novel nanopharmaceutical of camptothecin in clinical development, Curr Bioact Compd, 7, 8, 10.2174/157340711795163866 · DOI

Cited by

Sorted by citations

See all 879

Metadata

Authors
Tran, S., DeGiovanni, P., Piel, B., & Rai, P.
Affiliations
  • Department of Biological Sciences University of Massachusetts 01854 Lowell MA USA
  • Department of Chemical Engineering University of Massachusetts 1 University ave 01854 Lowell MA USA
ORCID
Rai, Prakash
Venue
Clinical and Translational Medicine
Publisher
Wiley
Published
2017-12
Volume
6
Issue
1
ISSN
2001-1326
DOI
10.1186/s40169-017-0175-0
PMC
PMC5725398
Cited by
879
References
10
Language
en
Licence
Funders
  • National Cancer Institute (R00CA153948, K99CA153948)
  • National Institutes of Health (K99CA153948, R00CA153948)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review